9 unknown. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Unknown 9 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study mirabegron - Overactive Bladder | Phase 4 | Unknown | Peking Union Medical College Hospital | 600 | 2022-07-15 | 2022-07-11 |
| Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial OnabotulinumtoxinA - Overactive Bladder Syndrome, Overactive Bladder | Phase 4 | Unknown | Augusta University | 100 | 2022-01-01 | 2021-12-15 |
| Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. Mirabegron, Tamsulosin - Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Unknown | St. Joseph's Healthcare Hamilton | 200 | 2021-12-01 | 2021-03-19 |
| Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB Tadalafil 5mg, Tamsulosin Hcl 0.4 mg, solifenacin 10 mg - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Unknown | Mansoura University | 60 | 2021-11-08 | 2022-08-10 |
| Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease Mirabegron, Placebo - Overactive Bladder, Parkinson Disease | Phase 4 | Unknown | Seoul National University Hospital | 144 | 2017-07-17 | 2018-01-30 |
| MIrabegron With oveRACtive bLadder Symptoms in mEn mirabegron, placebo - Overactive Bladder | Phase 4 | Unknown | Seoul National University Hospital | 462 | 2015-02-01 | 2015-02-11 |
| Premarin Versus Toviaz for Treatment of Overactive Bladder Toviaz, Premarin, Placebo cream - Overactive Bladder | Phase 4 | Unknown | The Cleveland Clinic | 90 | 2012-04-01 | 2017-04-20 |
| Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Solifenacin, Oxybutynin - Overactive Bladder | Phase 4 | Unknown | Adana Numune Training and Research Hospital | 500 | 2011-09-01 | 2011-08-26 |
| Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome DETRUSITOL - Overactive Bladder | Phase 4 | Unknown | Rambam Health Care Campus | 100 | 2006-02-01 | 2007-02-21 |
Urinary Bladder, Overactive (9) · Prostatic Hyperplasia (2) · Parkinson Disease (1) · Urinary Incontinence, Urge (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Lower Urinary Tract Symptoms (9) · Male Urogenital Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Urinary Bladder Diseases (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Urological Manifestations (9) · Genital Diseases (2) · Genital Diseases, Male (2) · Prostatic Diseases (2) · Basal Ganglia Diseases (1) · Brain Diseases (1)
mirabegron (4) · Solifenacin Succinate (2) · Tamsulosin (2) · Botulinum Toxins, Type A (1) · Estrogens (1) · Estrogens, Conjugated (USP) (1) · Sugars (1) · Tadalafil (1) · Tolterodine Tartrate (1) · fesoterodine (1) · oxybutynin (1)
Seoul National University Hospital (2) · Adana Numune Training and Research Hospital (1) · Augusta University (1) · Mansoura University (1) · Peking Union Medical College Hospital (1) · Rambam Health Care Campus (1) · St. Joseph's Healthcare Hamilton (1) · The Cleveland Clinic (1)
South Korea (2) · Canada (1) · Egypt (1) · Israel (1) · Turkey (Türkiye) (1) · United States (1)
Ahana Gaurav (1) · Ahmed Elhefnawy (1) · Alexandriah Alas, MD (1) · Anil Kapoor, MD, FRCSC (1) · Emily Grandprey, DO (1) · Emily Lluch (1) · Eric Hurtado, MD (1) · Ilan Gruenwald, MD (1) · Jennifer Lanzer, MD (1) · Mohammed Hegazy (1) · Murat Api, M.D., Ph.D. (1) · Seung-June Oh, MD (1)